March 7 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O:
VERTEX ANNOUNCES UK MHRA APPROVAL OF ALYFTREK® (DEUTIVACAFTOR/TEZACAFTOR/VANZACAFTOR), A ONCE-DAILY NEXT-IN-CLASS CFTR MODULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
VERTEX PHARMACEUTICALS INC - WORKING WITH NICE AND NHS FOR ALYFTREK ACCESS